Trials Sponsors Conditions Drugs Pricing

Conditions

Vogt Koyanagi Harada Disease

Keywords

Vogt-koyanagi Harada, Suprachoroidal injection

Outcome Measures

Primary Outcomes (1)

Best Corrected Visual Acuity (LogMAR units)
Changes in vision from baseline upto 6 months follow up
6 months after injection

Secondary Outcomes (1)

Central Foveal Thickness measured by Optical Coherence Tomography
Upto 6 months after SCTA injection

Other Outcomes (1)

Intraocular pressure measured by Goldmann applanation tonometry
6 months after injection

Study Arms (2)

SCTA injection (n=6 eyes)

ACTIVE COMPARATOR

Suprachoroidal Trimacinolone Acetonide injection 4mg/0.1ml, single dose, follow up for 6 months.

Drug: Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease

Non-injected eyes (Standard Treatment) (n=6 eyes)

NO INTERVENTION

Non-injected eyes on systemic steroids (standard treatment) and follow up for 6 months

Interventions

Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH diseaseDrug

Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease

Also known as: SCTA for Exudative RD in VKH disease

SCTA injection (n=6 eyes)

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age47 Years - 52 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

patients diagnosed as VKH serous retinal detachment in the acute phase whom BCVA is not improving after 2 weeks from starting systemic steroids.

You may not qualify if:

Sponsors & Collaborators

Benha University
Otherlead

Study Sites (1)

Ophthalmology department,Benha University and Ebsar eye center,Benha,EGYPT

Banhā, Qualiobeya, 13511, Egypt

MeSH Terms

Conditions

Uveomeningoencephalitic Syndrome

Condition Hierarchy (Ancestors)

Autoimmune Diseases of the Nervous SystemNervous System DiseasesUveitisUveal DiseasesEye DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

Ahmed Abdelshafy, MD
Benha University, faculty of medicine
PRINCIPAL INVESTIGATOR
Marwa Abdelshafy, MD
Benha University, faculty of medicine
STUDY DIRECTOR
Mohamed Anany, MD
Benha University, faculty of medicine
STUDY CHAIR

Enrollment

6 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 2 3
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Lecturer of Ophthalmology

Study Record Dates

First Submitted

August 26, 2021

First Posted

September 1, 2021

Study Start

April 1, 2020

Actual (reported)

Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Other Outcomes (1)

Study Arms (2)

SCTA injection (n=6 eyes)

Non-injected eyes (Standard Treatment) (n=6 eyes)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Other Outcomes (1)

Study Arms (2)

SCTA injection (n=6 eyes)

Non-injected eyes (Standard Treatment) (n=6 eyes)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations